Stanford V

Stanford V (usually spoken as Stanford Five) is a chemotherapy regimen (with or without accompanying Radiation therapy) intended as a first-line treatment for Hodgkin lymphoma. The regimen was developed in 1988, with the objective of maintaining a high remission rate while reducing the incidence of acute and long term toxicity, pulmonary damage, and sterility observed in alternative treatment regimens such as ABVD.[1] The chemical agents used are:

Drug Regimen[2][3]

DrugDoseModeDays
Doxorubicin25 mg/m2IVDays 1 and 15
Vinblastine6 mg/m2IVDays 1 and 15
Chlormethine6 mg/m2IVDay 1
Vincristine1.4 mg/m2 (max 2 mg)IVDays 8 and 22
Bleomycin5 units/m2IVDays 8 and 22
Etoposide60 mg/m2IVDays 15, 16
Prednisone40 mg/m2POQ2D

The chemotherapy part of Stanford V treatment can last anywhere from 8 to 12 weeks, depending on the staging of the disease. In many cases, this is followed by radiation therapy for anywhere from 2 to 6 weeks to the affected areas of the body.

Stanford V is a more rigorously administered form of chemotherapy, with treatments roughly twice as fast as those of other Hodgkin lymphoma treatments. However, in a randomized controlled study, Stanford V was inferior to ABVD.[4] This study has been criticized for not adhering to the proper Stanford V protocol. Specifically, the radiation therapy component following chemotherapy was not properly administered in the Italian study. A retrospective study from the Memorial Sloan-Kettering Cancer Center displayed results similar to the Stanford Cancer Center's own experience. The study concluded that, "Stanford V with appropriate radiotherapy is a highly effective regimen for locally extensive and advanced HL."[5]

  • Lymphoma Information Network
  • Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA (February 2002). "Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial". J. Clin. Oncol. 20 (3): 630–7. doi:10.1200/jco.20.3.630. PMID 11821442.
  • Includes table for schedule

References
  1. Bartlett NL, Rosenberg SA, Hoppe RT, et al. (1995). "Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report". J. Clin. Oncol. 13 (5): 1080–1088. PMID 7537796.
  2. "Cancer Care Ontario". Formulary. Retrieved 2011-05-27.
  3. Horning, SJ; Williams J, Bartlett NL; et al. (March 2000). "Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin's Disease: Eastern Cooperative Oncology Group Pilot Study E1492". Journal of Clinical Oncology. 18 (5): 972–980. doi:10.1200/jco.2000.18.5.972. PMID 10694546.
  4. Gobbi, PG; Levis, A; Chisesi, T; et al. (2005). "ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi". J. Clin. Oncol. 23 (36): 9198–207. doi:10.1200/JCO.2005.02.907. PMID 16172458.
  5. Edwards-Bennett SM, Jacks LM, Moskowitz CH, Wu EJ, Zhang Z, Noy A, Portlock CS, Straus DJ, Zelenetz AD, Yahalom J (2010). "Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience". Ann. Oncol. 21 (3): 574–81. doi:10.1093/annonc/mdp337. PMID 19759185.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.